Stockscreener 앱 받기
111.04
1.82%
-2.06
시간 외 거래:
111.04
전일 마감가:
$113.10
열려 있는:
$111.95
하루 거래량:
7.89M
Relative Volume:
0.91
시가총액:
$192.95B
수익:
$44.33B
순이익/손실:
$6.50B
주가수익비율:
29.87
EPS:
3.717
순현금흐름:
$7.40B
1주 성능:
-4.49%
1개월 성능:
+1.80%
6개월 성능:
-16.47%
1년 성능:
-19.37%
1일 변동 폭
$110.52
$112.00
1주일 범위
$110.52
$116.81
52주 변동 폭
$105.27
$139.15
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
111.04 | 196.53B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
370.50 | 146.14B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
93.01 | 122.74B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
72.99 | 107.15B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
83.89 | 49.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Abbott IP chief: ‘Firms without AI policies scare me’ - Life Sciences Intellectual Property Review
Abbott Laboratories $ABT Shares Sold by Victory Capital Management Inc. - MarketBeat
Abbott Laboratories $ABT Shares Sold by Orion Porfolio Solutions LLC - MarketBeat
Abbott Faces Trial Over Claims Its Infant Formula Caused Bowel Disease in Premature Babies - The Indian Practitioner
Trial over Abbott Laboratories’ formula for premature babies set to begin this week - Times West Virginian
Crossmark Global Holdings Inc. Purchases 12,373 Shares of Abbott Laboratories $ABT - MarketBeat
Respiratory Disease Testing Market Global Forecast Report 2026-2032: $9.32 Bn Opportunities in Integrating Advanced Diagnostics, Leveraging Partnerships, and Enhancing Supply Resilience - GlobeNewswire Inc.
Abbott Labs to face trial on infant formula - The Economic Times
Trial over Abbott Laboratories’ formula for premature babies set to begin in Chicago this week - The Daily Gazette
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Daywatch: Trial over Abbott Laboratories’ formula for premature babies set to begin - Chicago Tribune
Abbott set to face trial over claims premature infant formula caused deadly disease - Reuters
Trial over Abbott Laboratories’ formula for premature babies set to begin in Cook County this week - Chicago Tribune
Dimensional Fund Advisors LP Purchases 169,115 Shares of Abbott Laboratories $ABT - MarketBeat
US002824BU37 Bond Price and Chart — SWB:US002824BU37 - TradingView
Abbott Laboratories EVP Cushman sells $30k in stock By Investing.com - Investing.com Australia
Abbott Laboratories EVP Cushman sells $30k in stock - Investing.com South Africa
A4EQ5K Bond Price and Chart — GETTEX:A4EQ5K - TradingView
Insider Selling: Abbott Laboratories (NYSE:ABT) EVP Sells 613 Shares of Stock - MarketBeat
Abbott Laboratories (NYSE:ABT) EVP Sells $102,288.30 in Stock - MarketBeat
Insider Selling: Abbott Laboratories (NYSE:ABT) EVP Sells 263 Shares of Stock - MarketBeat
Insider Sell: Elizabeth Cushman Sells Shares of Abbott Laborator - GuruFocus
Abbott (ABT) SVP Eric Shroff logs share sale and tax disposition - Stock Titan
Abbott Laboratories (ABT) EVP logs 4,997-share tax-withholding disposition on Form 4 - Stock Titan
Abbott (NYSE: ABT) EVP logs share sale and tax disposition - Stock Titan
Abbott (NYSE: ABT) EVP Morrone logs stock sale and tax share disposition - Stock Titan
Abbott Laboratories (ABT) EVP logs tax-withholding disposition of 8,577 shares - Stock Titan
Abbott Laboratories (NYSE: ABT) VP reports sale and tax share disposal - Stock Titan
Abbott Laboratories (ABT) CFO uses 7,441 shares to cover tax withholding - Stock Titan
Abbott (ABT) EVP logs stock sale and tax-withholding share disposal - Stock Titan
How FDA Approval of CardioMEMS Hero Remote Monitor At Abbott (ABT) Has Changed Its Investment Story - Yahoo Finance
Abbott Labs Finishes Off Suit Over Google, Meta Data Sharing - Bloomberg Law News
Abbott Laboratories Spent $20 Billion to Enter Cancer Diagnostics: Why Analysts See 60% Upside - TIKR.com
Exact Sciences Holders Back Abbott Deal As Valuation Gap Draws Focus - simplywall.st
Better Value & Growth: STE, RMD Lead Abbott Laboratories Stock - Trefis
Abbott Laboratories Stock: Is This Quiet Health Tech Giant Your Next Big US Play? - AD HOC NEWS
Abbott Beats Data Sharing Suit Over Glucose Tracking Trial - Law360
Is Abbott Laboratories (ABT) Pricing Look Attractive After Recent Share Price Weakness? - simplywall.st
[144] ABBOTT LABORATORIES SEC Filing - Stock Titan
Abbott (ABT) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
Futures Contracts for Abbott Laboratories Futures - TradingView
NICE recommends leadless pacemakers to treat slow heart rhythms - BioWorld MedTech
2 Reasons to Like ABT and 1 to Stay Skeptical - StockStory
Abbott wins FDA approval for updated heart failure monitoring device - MedTech Dive
Abbott Laboratories (NYSE:ABT) Emerges as a Top Dividend Stock with Strong Fundamentals - ChartMill
Fisher Asset Management LLC Raises Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Laurel Wealth Advisors LLC - MarketBeat
Abbott Laboratories stock forecast for 2030: Exact Sciences acquisition reshapes growth outlook toward $180 - Traders Union
Antibiotics Market - GlobeNewswire Inc.
Rafferty Asset Management LLC Purchases 9,290 Shares of Abbott Laboratories $ABT - MarketBeat
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.08%
자본화:
|
볼륨(24시간):